Millennium Management LLC Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Millennium Management LLC lessened its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 87.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 30,470 shares of the specialty pharmaceutical company's stock after selling 222,273 shares during the period. Millennium Management LLC owned about 0.06% of Supernus Pharmaceuticals worth $1,102,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Supernus Pharmaceuticals by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock worth $1,033,000 after buying an additional 1,083 shares in the last quarter. Barclays PLC lifted its stake in shares of Supernus Pharmaceuticals by 88.3% in the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock worth $3,393,000 after buying an additional 51,005 shares in the last quarter. Empowered Funds LLC bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth approximately $1,498,000. Smartleaf Asset Management LLC lifted its stake in shares of Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after buying an additional 870 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in shares of Supernus Pharmaceuticals by 6.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock worth $2,169,000 after buying an additional 3,495 shares in the last quarter.

Analysts Set New Price Targets

Several research firms recently commented on SUPN. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. Wall Street Zen raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, May 16th.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock traded up $0.81 during trading on Friday, hitting $33.15. 354,750 shares of the company's stock traded hands, compared to its average volume of 478,015. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28. The stock has a market capitalization of $1.86 billion, a P/E ratio of 30.98 and a beta of 0.71. The business has a 50-day simple moving average of $31.95 and a 200-day simple moving average of $34.45.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.